Caribou Biosciences (CRBU) vs CervoMed (CRVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CervoMed (CRVO) has outperformed Caribou Biosciences (CRBU) over the past year, losing 63.1% versus a loss of 82.0%. Over five years, CRVO leads with a -90.9% price change compared with -97.7% for CRBU. Caribou Biosciences is the larger company by market cap ($51.6 million vs $49.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | CRVO |
|---|---|---|
| Share price | $0.4812 | $3.28 |
| Market cap | $51.59M | $49.59M |
| 1-day change | -22.06% | +3.14% |
| YTD return | -69.74% | -58.48% |
| 1-year return | -82.04% | -63.15% |
| 5-year return | -97.69% | -90.89% |
| EPS (TTM) | $-1.08 | $-3.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $10.00 |
| 52-week low | $0.45 | $2.13 |
| Distance from 52-week high | -86.39% | -67.20% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1094.93% | +369.51% |
| Average volume | 2.14M | 339.08K |
| Shares outstanding | 107.21M | 15.12M |
| Employees | 97 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVO has outperformed CRBU by 18.9 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
CRBU vs CRVO FAQ
Which is bigger, Caribou Biosciences or CervoMed?
Caribou Biosciences (CRBU) is larger, with a market capitalization of $51.59M compared with $49.59M for CervoMed (CRVO).
Which stock has performed better over the past year, CRBU or CRVO?
CRVO returned -63.15% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and CervoMed in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Caribou Biosciences and Biotechnology: Pharmaceutical Preparations for CervoMed.